Filing Details

Accession Number:
0001104659-18-042308
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-26 16:53:54
Reporting Period:
2018-06-25
Accepted Time:
2018-06-26 16:53:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674365 Aptinyx Inc. APTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1547100 Liam Ratcliffe C/O Aptinyx Inc.
909 Davis Street, Suite 600
Evanston IL 60201
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-25 1,047,450 $0.00 1,047,450 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-06-25 1,197,076 $0.00 2,244,526 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-06-25 552,208 $0.00 2,796,734 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-06-25 243,345 $0.00 243,345 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-06-25 125,000 $16.00 2,921,734 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-06-25 125,000 $16.00 368,345 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Convertible Preferred Stock Disposition 2018-06-25 28,895,188 $0.00 1,047,450 $0.00
Common Stock Series A-2 Convertible Preferred Stock Disposition 2018-06-25 33,022,786 $0.00 1,197,076 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-06-25 15,233,315 $0.00 552,208 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-06-25 6,712,986 $0.00 243,345 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.
  2. These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities.
  3. The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  4. These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. ("NLV Biopharma"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. ("NLBA-I"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities.
  5. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  6. On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering.